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For a long time the main goal in prostate cancer care has been to
prolong the life of patients. However, with increased survival of
men with prostate cancer leading to a long life after diagnosis and
treatment, interest in quality of life in addition to quantity of life
has increased. The therapeutic options for prostate cancer may
provide control of the tumour for several years, even if the tumour is
not radically treated, but the treatment as well as the tumour itself
often influences general well-being in several ways, in particular in
sexual and urinary functions. Metastatic spread may cause
longlasting pain, although this may be avoided with palliative
radiotherapy and effective analgesia (Portenoy and Lesage, 1999).
However, this requires a high availability of the health care
providers. If the prostate cancer care is to be effective for the
whole population, the barriers to health care have to be reduced,
especially for those who have the greatest difficulties in finding
their way in the health care system (Mandelblatt et al, 1999). 
Psychometric instruments are used for the assessment of quality
of life. These typically contain questions presented as scales, each
measuring one aspect of health-related quality of life. In the case
of prostate cancer, mobility, urinary and sexual function, self-care,
social relationships and mood are of particular interest. For
patients with advanced tumours, pain and how it interferes with
physical activity, sleep, and other daily functions become funda-
mental issues. 
There have been health-related quality of life studies using
psychometric tests following radical prostatectomy and radio-
therapy (Pedersen et al, 1993; Krupski et al, 2000; Fowler et al,
2000; Helgasson et al, 1997), hormonal treatment (Rosendahl et al,
1999) and watchful waiting (Jönler et al, 1998) as well as for men
undergoing screening for prostate cancer (Smith et al, 2000) based
on selected cases under experimental conditions. Our under-
standing of the quality of life of men with prostate cancer has also
been augmented by CaPSURE, a large national observational data-
base of patients with prostate cancer in the USA (Lubeck et al,
1999). However, in order to be able to understand how quality of
life for men in the community as a whole is affected by prostate
cancer, population-based studies without selection based on treat-
ment or hospital enrolment are required. 
As regards quality of life, a knowledge of the prevalence of pain
amongst all men with prostate cancer is necessary for effective
management of the disease. Pain is often the most dreaded feature
for patients with cancer and it is that aspect of quality of life that
concerns many of them most (Wang et al, 1999). Studies have
shown that doctors often underestimate the importance of pain
among cancer patients and do not provide adequate analgesia
(Cleeland et al, 1994; Larue et al, 1995). The presence of pain as a
component of quality of life has been studied on a large scale
amongst patients with advanced tumours (Cleary et al, 1995;
Curran et al, 1997), but to reach a full understanding of the
epidemiology of pain, not limited to advanced or terminal cases,
all cancers in a population-based setting have to be studied
(Greenwald et al, 1987). 
The first aim of our study was to provide baseline data on the
prevalence of pain in a population-based sample of men with
prostate cancer. The second was to explore how health-related
quality of life was affected by the disease. The third was to investi-
gate the impact pain has on daily functions and quality of life
amongst men with prostate cancer. The fourth was to evaluate
factors influencing pain and quality of life amongst men with
prostate cancer. The fifth was to find any potentially undertreated
groups of people with pain. In order to achieve this we sent a ques-
tionnaire based on 2 validated instruments to all prevalent cases of
prostate cancer in the county of Östergötland, Sweden. 
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Study base 
The basic source of information was a questionnaire sent to all
men with prostate cancer in the county of Östergötland. Östergöt-
land is one of 3 counties of the South-East Health Care region
(Östergötland, Jönköping and Kalmar county). The total popula-
tion in Östergötland was 412 000 in 1999. It has 2 peripheral
hospitals and 1 central referral hospital. All cases of prostate
cancer were identified in the National Tumour Register, which was
started in 1958 as a population-based cancer register and has a
coverage greater than 98% (Mattsson, 1977). It contains data on all
tumours diagnosed, including personal number and date of diag-
nosis. For cases diagnosed in 1987 or later, additional data on
tumour stage, grade and treatment were extracted from the South-
East Region Prostate Cancer Register, which serves as an exten-
sion of the National Tumour Register (Sandblom et al, 2000). For
cases diagnosed prior to 1987, this information was achieved
through a review of their case histories at each respective urology
department. The central death register was searched for cases that
had died before the start of the study and these were excluded. All
data in the questionnaire were converted into electronic form by
scanning and then checked once manually. 
Subjects 
There were 7199 cases of prostate cancer diagnosed in Östergöt-
land and registered in the National Tumour Register up until
December 31 1998; of these 4474 were registered as dead in the
Tumour Register. A total of 30 cases were excluded due to an
incomplete personal registration number, diagnosis before 1969 or
because they were born before 1900. The remaining 2695 cases
were cross-linked with the National Population Register, which
resulted in the further exclusion of 1145 deceased cases, 8 cases in
which matching with the personal registration number was impos-
sible to achieve and 40 cases who had moved out of the county. In
a repeated matching with the population register in November
1999 an additional 60 deaths were recorded, leaving 1442 cases in
the group studied. 
The first letter with the questionnaire and an explaining letter
was sent in September 1999. Two letters were sent 2 weeks and 4
weeks after the first letter as reminders to non-responders. A nurse
was available on the telephone at each of the 3 urology depart-
ments in the county to provide general information and clarifica-
tion of the questions. Of the remaining 1442 still alive at the start
of the study, there were 1243 (86%) responders. The reasons for
drop-out were: non-responders (145), inability to answer due to
disease (34), absence of answers in the returned questionnaires (8),
refusal to answer (5), not reachable at noted address (4) change of
address (1) answered by wrong person (1), and obviously inaccu-
rate answers (1). Of the 1243 responders, 78 had prostate cancer
diagnosed before 1987. 
The primary treatment of the 1243 responders was distributed
between watchful waiting (n = 582), palliative treatment including
bilateral orchiectomy (n = 127), GnRH-analogues (n = 238),
transurethral resection of the prostate (TUR-p, n = 37) antiandro-
gens (n = 15) and oestrogen (n = 8), and treatment with curative
intent, including radical prostatectomy (n = 156), external radia-
tion therapy (n = 58) and brachytherapy (n = 16). Information on
treatment was missing for 6 cases. Of those initially managed with
watchful waiting, 15 later received treatment with curative intent
and 184 with palliative treatment. Similarly, of those who initially
were treated with curative intent, 30 patients later received pallia-
tive treatment and of those initially receiving palliative treatment,
4 were later treated with curative intent. At the time of the ques-
tionnaire, 383 men were thus managed with watchful waiting; 635
patients received palliative treatment and for 219, treatment with
curative intent was registered as the last treatment received. 
Questionnaire 
The questionnaire was composed as a combination of the EuroQol,
parts of the Brief Pain Inventory (BPI) form and 8 specially
designed questions. Altogether there were 26 questions. 
EuroQol is a non-disease-specific instrument for describing and
evaluating health-related quality of life (EuroQol© Group, 1990).
It was developed as an internationally standardized complement to
other health status measures with 5 questions covering the basic
domains common to generic health status and a visual analogue
scale (VAS) for indication of general health state. The answers to
the first 5 questions can be derived to produce an overall index of
health status (EQ-5D). A validation of EuroQol in Sweden has
shown a striking similarity to studies in other European centres
(Brooks et al, 1991). It also has a good test–retest reliability (van
Agt et al, 1994). In 1999 The EuroQol was also sent to a randomly
selected group of 2700 men in the country council of Östergötland,
forming a reference group to the presently studied group. 
The BPI is an instrument designed to assess the severity and
impact of pain on daily functions among patients with cancer pain
and pain due to chronic diseases. It rates the degree to which pain
interferes with mood, walking and other physical activity, work,
social activity, relations with others and sleep. The BPI has been
validated in several studies in which the instrument was applied to
cancer patients and others who had pain (Serlin et al, 1995;
Cleeland et al, 1996). It has also been shown to have respectable
reliability (Cleeland and Ryan 1994). It contains 4 questions on
pain severity and 7 questions on how pain interferes with daily
functions. 
In addition to the standardized questions from the EuroQol and
BPI, 8 specially designed questions were included: 
1. How would you rate your general physical condition during
the previous week? (1–7) 
2. How would you rate your general quality of life during the
previous week? (1–7) 
3. How efficient do you think your pain treatment is? (1–4) 
4. Do you receive treatment in time when you have pain? (1–4) 
5. Do you suffer from any side effects of the treatment? (Yes/No) 
6. Which drugs do you take for pain or any other cause? 
7. How difficult has it been to get access to a nurse or physician
when needed the last half year? (5 grades from ‘always easy’
to ‘always difficult’ and a choice at ‘need of contact with
health care’) 
8. What is your marital state? (Single/Married). 
Pain management index 
In order to determine whether the patient was adequately managed
for his pain, a pain management index (PMI) was estimated
(Fowler et al, 1995). The index was derived by subtracting the
rating of most pain on the BPI questionnaire from a score
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the respondent. The analgesic drug score was defined according to
the World Health Organization’s (WHO’s) analgesic ladder: 0 for
no analgesics, 1 for non-opioids, 2 for weak opioids and 3 for
strong opioids. Based on the most pain as stated in the BPI ques-
tionnaire, the pain score (0–10) was categorized as 0 for no pain
(rating 0), 1 for mild pain (ratings 1–3), 2 for moderate pain
(ratings 4–7) and 3 for severe pain (ratings 8–10). A negative score
indicates undertreatment of the pain (Cleeland et al, 1994). 
Statistics 
In the analyses, localized tumours were defined as T0-2, NX/N0
and M0; all others were treated as advanced tumours. The treat-
ment was categorized into 3 groups: watchful waiting, palliative
treatment (including bilateral orchiectomy, GnRH-analogues,
TUR-p antiandrogens and oestrogen) and treatment with curative
intent (including radical prostatectomy, external radiation therapy
and brachytherapy). In a multivariate regression analysis, factors
predicting outcome from the BPI question regarding ‘pain on
average’ in the last week (11 grades) were assessed, including
patient age, marital state, time since diagnosis, presence of distant
metastases at time of diagnosis, and last received and rating of
health care availability, as independent variables. The treatment
was categorized as palliative, curative and watchful waiting, with
watchful waiting considered a reference category. The rating of
health care availability was divided into 3 categories: ‘no need of
contact’, ‘easy to get contact’ (always easy and usually easy to get
contact) and ‘difficult to get contact’ (neither easy nor difficult,
usually difficult and always difficult). ‘No need of contact’ and
‘difficult to get contact’ were included in the analysis and ‘easy to
get contact’ was treated as a reference category. 
Similarly, factors predicting health-related quality of life as
stated on the VAS in the EuroQol questionnaire were assessed in a
multivariate regression analysis, with age, marital state, time since
diagnosis, tumour stage (localized/advanced), last treatment
received, rating of pain on average in the last week and rating of
health care availability, as independent variables. As a question
about pain or discomfort is used when deriving the EQ-5D, we
preferred to use the VAS scale as a measure of quality of life in
order to avoid a tautology when testing how it is influenced by
pain on average. The difference between the general population
and the studied population in the EQ-5D score and the rating on
the EuroQol VAS scale was tested with Student’s t-test in the age
intervals of 45–54 years, 55–64 years and 65–74 years. A multi-
variate logistic regression analysis with age, treatment, marital
state, presence of distant metastases at diagnosis, time since diag-
nosis and rating of health care availability, was used to assess risk
factors for negative PMI. 
RESULTS 
The analyses presented in this report are based on the 1243 respon-
ders. The mean age of these men was 77.3 years (standard devia-
tion (SD) 8.0 years). The mean age of those who did not answer
the questionnaire was 81.6 years (SD 7.7 years). The mean interval
between diagnosis and answer to the questionnaire was 5.7 years
(SD 4.3 years).
Pain 
At the time of the survey, 500 men out of 1181 perceived some
pain during the past week (Table 1). The most pain during the past
week was stated as ‘severe’ by 148 men. ‘Pain on average’ was the
pain severity question that correlated most strongly with all the
pain interference questions, except for interference with sleep,
which correlated more strongly with ‘most pain last week’. The
mean rating of pain right now, including men rating the pain as 0,
was 1.8 (95% confidence interval [CI] ± 0.14) most pain past week
2.2 (± 0.17), least pain past week 1.2 (± 0.11) and pain on average
1.7(±0.13). The Cronbach alpha rating for these 4 different esti-
mates of pain was 0.97. The ratings from the interference ques-
tions, stratified for the rating of most perceived pain last week, are
shown in Table 2. The mean rating of the most pain in the past
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Table 1 BPI severity question ratings (row percentages) 
Variable No pain (rating 0) Mild pain (rating 1–4) Moderate pain (rating 5–6) Severe pain (rating 7–10) 
Pain right now 695 (60%) 258 (22%) 134 (11%) 79 (7%) 
Most pain last week 680 (58%) 184 (16%) 159 (14%) 143 (12%) 
Least pain last week 735 (63%) 323 (28%) 74 (6%) 34 (3%) 
Pain on average last week 679 (58%) 280 (24%) 158 (14%) 49 (4%) 
The ratings, ranging from 0–10, are classified as no pain (0), mild pain (1–4), moderate pain (5–6) and severe pain (7–10), (Serlin et al, 1995).
Only patients answering all questions were included (n = 1166). 
Table 2 Mean rating on the BP1 interference questions, ranging from 0–10 (± 95% confidence interval), stratified for rating on pain on average 
Rating of pain on average 
Factor No pain (rating 0) Mild pain (rating 1–4) Moderate pain (rating (5–6) Severe pain (rating 7–10) Total 
General activities 0.08 ± 0.05 2.84 ± 0.26 5.55 ± 0.33 7.26 ± 0.60 1.80 ± 0.16 
Mood 0.10 ± 0.05 2.58 ± 0.25 4.98 ± 0.38 5.86 ± 0.81 1.61 ± 0.15 
Walking 0.18 ± 0.08 3.34 ± 0.30 5.81 ± 0.43 7.16 ± 0.80 2.00 ± 0.17 
Work 0.09 ± 0.06 2.91 ± 0.32 5.45 ± 0.44 6.66 ± 0.86 1.71 ± 0.16 
Relations with other people 0.10 ± 0.06 1.83 ± 0.27 3.44 ± 0.43 4.80 ± 0.98 1.17 ± 0.13 
Sleep 0.13 ± 0.06 3.50 ± 0.74 5.21 ± 0.43 5.92 ± 0.88 1.88 ± 0.23 
Enjoyment of life 0.35 ± 0.12 3.19 ± 0.31 6.04 ± 1.25 6.86 ± 0.88 2.06 ± 0.24week in men with distant metastases at diagnosis (M1) was 2.6 
(± 0.34) and in men without known distant metastases 2.2 (± 0.09). 
As the ‘pain on average’ question was found to be the BPI pain
severity variable with the strongest correlation to the pain interfer-
ence questions, it was chosen as the dependent variable in a multi-
variate regression analysis of factors predicting pain. How the
different factors predict pain on average is shown in Table 3. The
following 3 factors were found to be significant in predicting pain:
‘difficult to contact health care’, ‘no need to contact health care’
and time since diagnosis. The mean rating of ‘pain on average’
depending on the health care availability is shown in Table 4
(together with other outcome variables). For men who had not
received any treatment at all, the mean rating on pain on average
was 1.6 (95% CI ± 0.24), for those who had received treatment
with curative intent 1.3 ( ± 0.29) and for those who had received
palliative treatment 1.93 ( ± 0.19). 
Health-related quality of life 
The answers to the question concerning mobility varied from no
problems (754), some problems (450) and confined to bed (14).
Similarly concerning self-care, the answers included no problems
(1059), some problems (137) and unable (28). The answers
concerning usual activities were: no problems (906), some prob-
lems (216) and unable (85). Concerning pain or discomfort, the
answers were: none (468), moderate (692) and extreme (60), and
concerning anxiety or depression, were: none (807), moderate
(393) and extreme (21). The mean ratings on the EuroQol VAS in
the present study compared to the ratings from the general
population in the County Council questionnaire are presented in
Figure 1 and the mean EQ-5D scores in Figure 2. There was no
significant difference in health-related quality of life between the
general population and the men with prostate cancer, neither for
EuroQol VAS or EQ-5D, in any of the age intervals from 45–74
years. Factors predicting the EuroQol VAS score in a multivariate
regression analysis are shown in Table 5. As there was a high
degree of co-linearity between the BPI questions, only the ‘pain
on average’ variable was included in the analysis. There were 4
independent factors found to be significant: pain on average, age,
difficulty in getting in contact with health care and palliative treat-
ment. The mean scores on the EuroQol VAS scale depending on
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Table 3 Factors predicting pain on average in a multivariate regression analysis 
Factor Standardized coefficient (beta)* t-value Significance 
Difficult to get in contact with health care† 0.131 4.307 < 0.001 
No need of contact with health care† – 0.127 – 4.107 < 0.001 
Time since diagnosis 0.080 2.493 0.013 
Treatment with curative intent† – 0.052 – 1.426 0.154 
Palliative treatment† – 0.025 0.716 0.474 
Presence of distant metastases at diagnosis† 0.021 0.682 0.495 
Age 0.019 0.562 0.574 
Marital status ‡ 0.015 0.519 0.604 
*Regression coefficient divided with the SD of each variable; †Positive = 1, Negative = 0; ‡Married = 1, Unmarried = 0. 
Table 4 Ratings of health care availability versus age, civil state and health-related quality of life as estimated by the number of men with EQ-5D scores ≤ 0.5
and the number of men who rated their quality of life on the VAS in EuroQol ≤ 50. The number of men rating severe pain (7–10) on the pain on average question
(BPI) and the number of men with negative PMI are also presented
Rating of availability No. Mean age Single living Pain on average rated  EQ-5D score ≤ 0.5 EuroQol VAS ≤ 50 Negative 
(years) severe  (7–10) PMI
No need for contact  506 78 131 (26%) 19 (4%) 42 (8%) 97 (19%) 130 (26%) 
with physician or nurse
in past 6 months
Always easy/usually  573 77 128 (22%) 25 (4%) 55 (10%) 147 (26%) 178 (31%) 
easy to get in contact
Neither easy nor    119 77 35 (29%) 6 (5%) 23 (19%) 54 (45%) 57 (48%) 
difficult/usually
difficult/always
difficult to get in
contact
Total 1198 77 294 (25%) 50 (4%) 120 (10%) 298 (25%) 365 (30%) 
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Figure 1 Mean values on the EuroQol VAS in a sample from the total male
population (Östergötland County Council questionnaire) and amongst those
with prostate cancer. 95% CIs are indicated the rating of health care availability are shown in Table 4. The
mean score on the EuroQol VAS for patients who had not received
therapy was 70 on a scale of 1–100 (95% CI ± 2). The score for
those who had received palliative treatment as last therapy was 64
± 2 and for those who had received curative treatment, 74 ± 3. The
relationship between the answers to the ‘pain on average’ ques-
tion and the rating on the EuroQOL VAS is shown in Figure 3. 
Pain treatment 
Altogether 995 (81%) study participants stated that they did not
receive analgesics at all, whereas 93 (8%) received non-opioids,
112 (9%) weak opioids and 35 (3%) strong opioids as the most
potent form of analgesia. The corresponding figures in men with
distant metastases at diagnosis (M1) were 50 (58%) for no anal-
gesia, 5 (6%) for non-opioids, 17 (20%) for weak opioids and 14
(16%) for strong opioids. Among the 637 men who had been given
palliative cancer-specific treatment, 29 (4.6%) received strong
opioids. The mean EQ-5D score was 0.39 for those who received
strong opioids as compared to 0.74 for the whole group. 
The answers to the question concerning effect of pain treatment
were distributed between very well 45 (17%), fairly well 174
(64%), rather poorly 41 (15%) and very poorly 9 (3%). Of the 272
participants who had received pain treatment, 75 (28%) stated that
they suffered from some form of side effect of their medication.
The answers to the question of whether pain treatment was given
within reasonable time varied from: always 78 (29%), most of the
time 145 (54%), seldom 33 (12%) and never 14 (5%). 
Altogether 379 (30.5%) participants had a negative PMI. In 67
cases, information was not complete enough to estimate PMI.
Factors predicting the risk for negative PMI in a multivariate
logistic analysis are shown in Table 6. There were 3 factors found
to be significant: absence of distant metastases at diagnosis (MX
or MO), ‘difficult in contacting health care Professionals’ and ‘no
need to contact health care’. Of the 81 men with distant metastases
at diagnosis, 14 (17.3%) had a negative PMI. Of the 364 patients
who had not received therapy, 125 (34.3%) had a negative PMI.
The same figure for those who had received curative treatment as
last therapy was 53 out of 207 (25.6%), and for those who had
received palliative treatment, 199 out of 605 (32.9%). The percent-
ages of negative PMI depending on rating of health care avail-
ability are presented in Table 4. 
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Figure 2 Mean values on the EQ-5D score in a sample from the total male
population (Östergötland County Council questionnaire) and among those
with prostate cancer. 95% CIs are indicated 
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Figure 3 Mean ratings on the EuroQoL VAS depending on the answer to
the ‘pain on average question’. 95% CIs are indicated 
Table 5 Factors predicting health-related quality of life as estimated on the EuroQol VAS in a multivariate regression analysis 
Factor Standardized coefficient (beta)* t-value Significance 
Pain on average – 0.436 – 16.511 < 0.001 
Age – 0.173 – 5.779 < 0.001 
Difficulty into contacting health care professionals† – 0.118 – 4.370 < 0.001 
Palliative treatment† – 0.072 – 2.367 0.018 
No need of contact with health care† 0.042 1.532 0.126 
Time since diagnosis – 0.026 – 0.920 0.358 
Marital status‡ 0.018 0.663 0.507 
Tumour stage at diagnosis§ – 0.010 – 0.367 0.714 
Treatment with curative intent† – 0.007 0.207 0.836 
*Regression coefficient divided with the standard deviation of each variable; †Positive = 1, Negative = 0; ‡Married = 1, Unmarried = 0;
§Advanced = 1, Localized = 0. 
Table 6 Factors predicting negative PMI in multivariate logistic analysis 
Factor Exp (B) Significance 
Difficulty in contacting health care professionals* 0.47 < 0.001 
Presence of distant metastases at diagnosis* 2.94 < 0.001 
No need of contact with health care professionals* 1.28 0.082 
Treatment with curative intent* 0.69 0.087 
Time since diagnosis 1.00 0.48 
Marital status† 1.06 0.73 
Palliative treatment* 0.97 0.87 
Age 1.00 0.91 
*Positive = 1, Negative = 0; ‡Married = 1, Unmarried = 0. DISCUSSION 
Using the National Tumour Register with its rigorous measures to
obtain complete information (Mattsson, 1977) as a base for assem-
bling the sample, it has been possible to guarantee that the present
study is essentially population based. This is further ensured by the
high compliance rate of participants. The reply rate of 86% was
achieved partly due to the reminder letters and nurses available on
the telephone to provide assistance. 
More than half of the men included in the study stated that they
did not have any pain in all of the BPI pain severity answers (Table
1). The relatively small discrepancy between the 4 pain questions,
designed to reflect the variations in pain intensity during the
previous week, also indicate that the pain intensity remained on a
stable level. However, 25% stated moderate to severe pain on some
occasion during the past week, possibly representing men with
refractory tumours or men with generalized tumours who had not
yet received hormonal treatment. This number could probably be
reduced to 10% with an increased awareness of the prevalence of
pain among cancer patients and if the risk of under-reporting of
pain and non-compliance is taken into consideration (Portenoy and
Lesage, 1999). Although a large number of the men included in
our study had generalized cancer, pain from metastases can, in
most cases, be avoided if treated adequately (Portenoy and Lesage,
1999). Hormonal treatment usually has a good palliative effect on
the primary tumour as well as the metastases. An association,
although not significant, was also seen between age and pain. This
may have been influenced by a higher prevalence of pain among
older men in the general population. In a previous study carried
out in the UK, 50.4% of patients randomly drawn from general
practices reported chronic pain (Elliott et al, 1999). In this study,
pain due to arthritis and back pain dominated. Arthritis as well as
back pain of benign causes may also be widespread in the
population of predominantly older men in our study. 
Men with prostate cancer rated their quality of life slightly
lower on the VAS than healthy men of the same age (Figures 1 and
2), although the CIs overlapped. The very wide CIs for the
youngest age groups of men with prostate cancer are explained by
the small sample size in these groups. In the CI in the 45–54 year
age grap, there were only 7 men and in the CI in the 55–64 year age
grap, only 73. The difference in rating caused by absence or pres-
ence of prostate cancer was minor in comparison with the impact
of age, pain and treatment of the tumour. The quality of life for
men with prostate cancer who have not received palliative
treatment and who do not have pain from the cancer thus differs
very little from that of men of the same age in the general popula-
tion. 
In a previous study it has been shown that the functions in the
BPI questionnarie become impaired at a critical level of pain
severity, which varies for each specific function (Cleeland, 1990).
Ranking of the mean values on the pain interference questions in the
present study also follows the same order (Table 2), except for inter-
ference with work, which had a relatively lower mean, and interfer-
ence with walking, which had a relatively higher mean. These
differences may be the result of pure coincidence, but may also
reflect specific characteristics of men with prostate cancer. Very
few participants are in the age group in which they might have a
regular occupation, which makes interference with work become
less important. Metastases from prostate cancer are most often
localized to the lumbar spine and the pelvis, which may have a
strong effect on the affected person’s ability to walk. 
The data presented in this report show that assessment and treat-
ment of pain is essential for a good quality of life for patients 
with prostate cancer. This is of special importance for patients with
advanced tumours, although tumour stage at diagnosis was not
found to significantly influence either pain on average or quality of
life as rated on the EuroQol VAS. Since the time elapsed since
diagnosis was not constant, the extent of the tumour at the time of
response may have differed considerably. Accordingly, in the
absence of a significant association between tumour stage at diag-
nosis and pain rating, a significant association was found between
time since diagnosis and pain rating. However, when interpreting
the data, palliative treatment could be considered a surrogate
measure of tumour progression. Palliative treatment is usually not
given before the tumour has progressed to an advanced state or the
primary tumour is causing considerable local symptoms.
Consequently, palliative treatment was associated with more pain,
a lower quality of life and a higher proportion of patients receiving
strong opioids. The reduced quality of life associated with pallia-
tive treatment can also be the result of treatment-related symp-
toms, such as muscle atrophy, loss of libido, depression and
osteoporosis. 
The results indicate that the availability of a physician or nurse,
when needed, is of very great importance for patients with prostate
cancer. The rating of health care availability correlated strongly
with the measures of quality of life as well as ratings of pain. A
low rating for health care professional availability was also associ-
ated with a high percentage of negative PMI. However, 26% of the
patients who stated that they had no need of contact with a physi-
cian or nurse still had a negative PMI. Although the patients in this
group probably did not receive adequate pain treatment, they still
indicated that they are content with the health care provided. This
may be due to a lack of awareness among the patients that more
efficient analgesics may be provided or a tendency to dissimulate.
The association of a negative PMI with a high pain rating and low
quality of life may partly be explained by a tendency amongst
patients who feel general frustration to express discontent when
answering all questions. However, of greater importance is prob-
ably the ever-increasing load on the Swedish health care system,
resulting in congested outpatient departments and long waiting
lists to see a specialist. Old and often disabled men with prostate
cancer may often find it difficult to express their very specific
needs in a health care system adapted to patients without commu-
nication problems. There was a slight tendency for older patients
to find it more difficult to gain access to health care and they are
more often single (Table 4). One way of making health care more
available would be to delegate the follow up of men with prostate
cancer to a specially trained nurse and introduce more individual-
ized plans of follow up (Helgesen et al, 2000). 
Despite the nature of prostate cancer, with the possibility of
effective palliative treatment even for advanced tumours, there was
a small number of men who stated that they were receiving insuffi-
cient pain treatment that was not provided in time. As expected, a
low rating for health care availability was associated with a high
risk for negative PMI. However, in contrast to a previous study
(Cleeland et al, 1994), older age was not associated with an
increased risk of a negative PMI, nor was marital status. The
higher percentage of men with a negative PMI amongst those
receiving palliative therapy indicates that they represent an under-
treated group. Men with tumours in progress probably make up a
large proportion of this group and should be given high priority
when planning follow up. The paradoxical low percentage negative
502 G Sandblom et al
British Journal of Cancer (2001) 85(4), 497–503 © 2001 Cancer Research CampaignPMI in men with distant metastases at diagnosis is explained by
the larger fraction of patients receiving stronger analgesia, whereas
as the rating of most pain last week was essentially the same for
the whole group. 
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